Table 1 Efficacy of SARS CoV-2 Vaccines by Age Group in Phase III Clinical Trials
From: Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity
Vaccine | Type | Doses (interval) | Median Follow-up | Age Groups | N (vaccine vs placebo) | Efficacy (95% CI) | Primary Efficacy Outcome | Ref. |
|---|---|---|---|---|---|---|---|---|
BioNTech/Pfizer BNT162b2 | mRNA | 2 (3 weeks) | 2 months | All 16–55 > 55 | 18,198 vs 18,325 10,889 vs 10,896 7971 vs 7950 | 95.0 (90.0–97.9) 95.6 (89.4–98.5) 93.7 (80.6–98.8) | Confirmed CoVID-19 (symptoms in combination with PCR test) | [46] |
Moderna mRNA-1273 | mRNA | 2 (4 weeks) | 63 days | All 18–64 > 64 | 14,134 vs 14,073 10,551 vs 10,521 3583 vs 3552 | 94.1 (89.3–96.8) 95.6 (90.6–97.9) 86.4 (61.4–95.2) | Symptomatic Covid-19 with onset at least 14 days after the second injection | [47] |
Janssen Ad26.COV2-S | Viral vector | 1 | 58 days | All 18–59 > 59 | 21,895 vs 21,888 14,564 vs 14,547 7331 vs 7341 | 66.9 (59.0–73.4) 63.7 (53.9–71.6) 76.3 (61.6–89.0) | Moderate to severe–critical Covid-19 | [48] |
AstraZeneca/Oxford ChAdOx1 | Viral vector | 2 (4–12 weeks) | 61 days | All 18–64 > 64 | 21,587 vs 10.792 16,760 vs 8381 4827 vs 2411 | 74.0 (65.3–80.5) 72.8 (63.4–79.9) 83.5 (54.2–94.1) | Symptomatic illness | [49] |